EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma

Kelsey B Bennion, Julia Miranda R Bazzano, Danya Liu, Maylene Wagener, Chrystal M Paulos, Mandy L Ford

JCI Insight · 2025

DOI: 10.1172/jci.insight.182563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Kelsey B Bennion und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology PhD program. Hauptthemen laut MEDLINE: Receptors, IgG, CD8-Positive T-Lymphocytes, Melanoma, Macrophages. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy has emerged as a promising therapeutic modality but heterogeneity in patient responsiveness remains. Thus, greater understanding of the immunologic factors that dictate response to immunotherapy is critical to improve patient outcomes. Here, we show that fibrinogen-like protein 2 (Fgl2) is elevated in the setting of melanoma in humans and mice and plays a functional role in inhibiting the CD8 + T cell response. Surprisingly, the tumor itself is not the major cellular source of Fgl2. Instead, we found that macrophage-secreted Fgl2 dampens the CD8 + T cell response through binding and apoptosis of FcγRIIB + CD8 + T cells. This regulation was CD8 + T cell autonomous and not via an antigen-presenting cell intermediary, as absence of Fcgr2b from the CD8 + T cells rendered T cells insensitive to Fgl2 regulation. Fgl2 is robustly expressed by macrophages in 10 cancer types in humans and in 6 syngeneic tumor models in mice, underscoring the clinical relevance of Fgl2 as a therapeutic target to promote T cell activity and improve patient immunotherapeutic response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, IgGCD8-Positive T-LymphocytesMelanomaMacrophagesFibrinogenAnimalsMiceHumansImmunotherapyMice, Inbred C57BLCell Line, TumorFemale

Stichwörter der Autor:innen

Cancer immunotherapyImmunologyMacrophagesOncologyT cells

Substanzen

Receptors, IgGFibrinogenFGL2 protein, humanFCGR2B protein, human

Autor:innen und Institutionen

  • Cancer Biology PhD program.
  • Department of Surgery.
  • Winship Cancer Institute.
  • Immunology and Molecular Pathogenesis PhD program, and.
  • Emory Transplant Center, Emory University School of Medicine, Atlanta, Georgia, USA.

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • National Cancer Institute

Zitieren

APA

Bennion, K. B., Miranda R Bazzano, J., Liu, D., Wagener, M., Paulos, C. M., & Ford, M. L. (2025). Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma. JCI Insight. https://doi.org/10.1172/jci.insight.182563

Vancouver

Bennion KB, Miranda R Bazzano J, Liu D, Wagener M, Paulos CM, Ford ML. Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma. JCI Insight. 2025. doi:10.1172/jci.insight.182563

BibTeX
@article{Bennion2025,
  author = {Bennion, Kelsey B and Miranda R Bazzano, Julia and Liu, Danya and Wagener, Maylene and Paulos, Chrystal M and Ford, Mandy L},
  title = {Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma},
  journal = {JCI Insight},
  year = {2025},
  doi = {10.1172/jci.insight.182563}
}
Kostenlos starten →